Dan David Prize
Dan David Foundation
All Regions
11/30/2008
$1,000,000

The DAN DAVID PRIZE annually awards 3 prizes of US$ 1 million each for achievements having an outstanding scientific, technological, cultural or social impact on our world. Each year fields are chosen within the three Time Dimensions - Past, Present and Future. The laureates for a given year are chosen from these fields.

The Dan David Prize is unique in its flexible definition of dynamically changing fields of human knowledge and in its process of fostering the next generation of scholars. The laureates annually donate 20 scholarships of $15,000 each to outstanding doctoral students throughout the world, in the chosen fields.

Nominations 2009 > General Information and Procedure

The fields within the three Time Dimensions for 2009:

PAST: Astrophysics - History of the Universe
PRESENT: Leadership
FUTURE: Global Public Health

The deadline for receipt of nominations is November 30th, 2008.

General Information:
Nominees for the Dan David Prize may be individuals or organizations. Specific and unique projects may be included if the head of the project is a nominee.
Winners for each Time Dimension are selected by the Dan David Prize Board, based on the recommendations of an international committee composed of world-renowned figures in the relevant field.
The committee may decide to select more than one winner for a specific prize if their achievements are considered to be of equal merit and impact on the relevant field.
The Dan David Prize is granted according to merit, without discrimination based on gender, race, religion, nationality, or political affiliation.
The work for which a nominee's recognition is sought may represent a singular achievement, a series of achievements, or a life's work. Nominees are considered only if their work and contributions represent exceptional and profound achievements in their fields.
Nominations may be submitted to the Dan David Prize only in accordance with the Dan David Prize guidelines and procedure, as detailed on Dan David Prize website and nomination form.
If a nomination is received based upon a nominee's contribution to a specific project, each member of that project should be listed separately, and his/her contribution to the project should be emphasized, as detailed in the Dan David Prize form.
If a nominee has been awarded the Dan David Prize, his/her/its right to that prize is not transferable to any other person/group/organization at any time.
An individual or organization can only receive the Dan David Prize once for the same achievement and/or contribution.
Self-nominations are not accepted.
Prize winners are required to participate in the award ceremony and the attendant events.
Based on complete discretion, the Dan David Prize may also call on foremost academic, research, and public institutions, prominent NGOs, high-ranking colleges and universities, outstanding public and academic figures, and former laureates of the Dan David Prize to nominate exceptional candidates, complying with the Dan David Prize requirements as specified in these regulations.
Where the major publications of a nominee are not in English, the relevant review committee may seek the assistance of an additional jury, as required. If no competent jury is found to the satisfaction of the relevant review committee, the committee may request translations of the publications into English, the cost of which will be borne by the nominee or nominator. The Dan David Prize will inform the nominator of the possible costs of translations and will request his permission to proceed with the review.
Guidelines:
Criteria for submission of nominations:
The individual or institution being nominated has made a unique, profound contribution to humanity, on a global scale, in one of the selected fields for the year in which the nomination is being made.
Required documents (in ENGLISH only, doc rtf or pdf format, Ariel or Times New Roman Font, minimum size 12) to be sent by email to ddpnomin@post.tau.ac.il:
Nomination form (completely filled-out).
A detailed description of the nominee's work (1-2 pages), stipulating reasons why the nominee merits the Dan David Prize. Please refer to the importance of the work, its impact, and its projected influence in the relevant field.
A full Curriculum Vitae of the nominee, or details prospectus in case the nominee is an organization.
A list of the nominee's publications of the last 15 years.
A list of the nominee's most relevant publications, stating full bibliographical details.
A photo of the nominee in electronic format, to be used by the Dan David Prize in case of need (300 dpi, copyright free, high-definition).
Confirmation of receipt will be sent by email.

Nominators will be notified of the Dan David Prize decision regarding the fate of their nomination.

Epidemiologogist, Public Health Expert, Scientist, Virologist
Gates Award for Global Health
Bill & Melinda Gates Foundation
All Regions
10/31/2008
$1,000,000

The Gates Award for Global Health

The nomination deadline for the Gates Award is October 31, 2008.

In December, 2000, the Bill & Melinda Gates Foundation announced the establishment of the International Gates Award for Global Health. The Gates Award has been established to recognize an organization yearly that has made a major and lasting contribution to the field of global health.

The prize consists of a distinctive award sculpture and a prize amount of 1 million dollars.

The Gates Award for Global Health was established by the Bill & Melinda Gates Foundation to reward and exemplify organizations which have developed processes for improving health, especially in resource poor settings, with measurable results. The Gates Award for Global Health recognizes past achievements and the promise of continuing activity and improvement.

Any organization from any country in the world that has substantively improved the health and the lives of people in need may be nominated for the Gates Award for Global Health; the organization may be a charitable institution, a private company, or a public entity.

Nominations will be considered by an international jury consisting of health professionals from developing countries and the Global Health Council's Board of Directors. Nominations submitted will be reviewed by this jury and a winner will be selected. The jury member names will be publicized on the Global Health Council website once it is established.

The award will be presented in Washington, D.C., at a special Awards Ceremony during the Global Health Council's Annual International Conference. The winner's name is embargoed until the time of the ceremony.

Global Health Council

1111 19th Street, NW - Suite 1120
Washington, DC 20036
Tel (202) 833-5900
Fax (202) 833-0075

Epidemiologogist, Public Health Expert, Public Health Worker, Public Servant
Request for Proposals--Smallpox Eradication Monument
Board and the Secretariat of the Smallpox Eradication Commemoration
All Regions
10/31/2008
$25,000

Request for Proposals for the Design
of a  Smallpox Eradication Monument
1.
Request for Proposals
The Board and the Secretariat of the Smallpox Eradication Commemoration - 2010 (SEC2010), through this Request for Proposals (RFP), invites designs for a work of public art to commemorate the eradication of smallpox. It will be located in a publicly-accessible area on the exterior grounds of the headquarters of the World Health Organization (WHO) in Geneva, Switzerland. The winning design will be awarded US$25,000 and each of four runners-up will receive $5,000.
2.
1Background
The year 2010 will mark the 30th anniversary of the World Health Assembly (WHA) formally confirming the report of the Global Commission for the Certification of Smallpox Eradication marking the elimination of this scourge of mankind.1 This unprecedented and lasting achievement of nations working together to benefit all the world’s people will be recognized with a “Monument” to inspire and educate the public of what can be achieved through global cooperation.
The Monument will be unveiled in May 2010 during the annual meeting of national ministers of health at the WHA at WHO headquarters. Private donations will fund the Monument and related commemoration activities, including a documentary film, an illustrated history book, and scientific symposia.
3.
2Monument Specifications
3.1.
7Type and material of structure
The proposed Monument may be of traditional or novel format, including one or a combination of the following, listed alphabetically, and not to the exclusion of others unlisted:

Architectural construct

Bas-relief

Mobile

Plaque

Sculpture
It should be constructed of metal, stone, concrete, glass, ceramic, and/or other durable materials.
1 The complete history of the global effort is documented in: Fenner F, Henderson DA, Arita I, Ježek Z, Ladnyi ID, eds. Smallpox and its Eradication. Geneva: World Health Organization, 1988, 1460 pages (ISBN-13: 9789241561106). The entire textbook is available online via URL hotlinks from this index file: http://whqlibdoc.who.int/smallpox/9241561106.pdf.
Smallpox Eradication Commemoration 2010 – RFP: Monument 12 August 2008 Page 2 of 7
3.2.
8Location
The Monument will be placed on the front entrance lawn of WHO Headquarters, in Geneva Switzerland (see http://earth.google.com coordinates: 46.233246° North latitude, 6.13437° East longitude). The exact location will be determined by WHO.
3.3.
9Size
The Monument “footprint” should be of comparable area (approximately 4 square meters) as the existing sculpture honoring onchocerciasis control2 on the lawn in front of the main entrance to WHO. Its maximum height should be 3 meters or less above grade. Any components higher than 1 meter above grade should be "light and airy" for harmony with its aesthetic and architectural surroundings.X2X Bulky, view-blocking designs may be disadvantaged in the selection process.
3.4.
10Maintenance-free
The Monument should be maintenance-free. No parts requiring electricity, water, or mechanical maintenance are allowed. Future external illumination of the Monument would be at the discretion of WHO.
3.5.
11Signage
Design proposals should include suggestions for how and where textual content will be integrated into or supplement the Monument on necessary plaques, engravings, or signs. Proposals optionally may suggest specific text (in English or with English translation), however the content of any signage will be determined by the SEC2010 Board and WHO.
4.
3Submission Requirements and Details
4.1.
12Eligibility
Anyone or any organization is invited to submit proposals for the Monument, including veterans of smallpox eradication efforts and employees of the WHO.
4.2.
13How to submit
Design proposals should be in English (or accompanied by full English translation), and submitted in accordance with the instructions on the APPLICATION FORM, the last page of this announcement, along with any supplementary information and materials.
4.3.
14Submission deadline
Submissions must be received on or before 31 October 2008 at 23:59 hours (11:59 p.m.) Greenwich Mean Time/Universal Time Coordinated (6:59 p.m. Eastern Standard Time USA; 00:59 next day Central European Time; 08:59 next day Japan Standard Time).

Emory Global Health Institute mailing address:

1599 Clifton Road, NE
6th Floor
Atlanta, GA 30322

Emory Global Health Institute phone number:

404-727-1433

Historian, Artist, Virologist
Institutional Program Unifying Population and Laboratory Based Sciences
Burroughs Wellcome Fund
All Regions
03/02/2009
$500,000

Institutional Program Unifying Population and Laboratory Based Sciences

Application deadlines for 2010 awards:

Letter of Intent: March 2, 2009 by 4:00 p.m. Eastern Time
Full Application (by invitation only): May 15, 2009 by 4:00 p.m. Eastern Time
By electronic application only.

Five-year institutional training awards provide $500,000 a year to bridge the gap between the population and computational sciences and the laboratory-based biological sciences. The award will support the training of researchers between existing concentrations of research strength in population approaches to human health and in basic biological sciences. The goal is to establish training programs by partnering researchers working in schools of medicine and schools (or academic divisions) of public health.

Eligibility
Understanding human health will be a focal priority for the programs that are funded. There is ample room for building on institutional strengths to achieve this focus, for example: institutional interests in chronic diseases, autoimmune diseases, infectious diseases, genetic diseases, toxicology and environmental exposures, reproductive health, and other areas where questions relating to human health are ripe for exploration at both the population and molecular scales. Likewise, institutional strengths in applied mathematics and modeling, statistics, genomics, bioinformatics and other informatics and data-driven sciences including geography and demographics, and phenomic approaches could provide excellent foundations for programs which encourage such work, as would strengths in population biology; epidemiology; human or disease ecology, anthropology, econometrics, and other population-focused quantitative fields.
Supported programs will train graduate students to the Ph.D. level, but programs may additionally propose giving training access to postdoctoral fellows, medical students, medical residents, masters students, undergraduates, or other kinds of trainees. Some examples of problems where such an approach would be beneficial include but are not limited to

multifactorial disease processes
evolution of and relationships between host, pathogen, vector, and reservoirs
biomarker identification and validation
effects of environmental exposure to toxins, allergens, and immunogens

Proposals

Degree-granting institutions in the U.S. or Canada may submit applications.
Proposals must be driven by core components within medical and public health schools, but beyond those required components, departments or centers located within non-medical parts of a university, existing inter-institutional collaboratives, research museums, free-standing research institutes, and other non-profit institutions that provide advanced-level training are all acceptable as potential additional partners. Dental, osteopathic, and veterinary medical schools are appropriate applicants.
Comparative medicine and animal science departments are advised to discuss their planned proposal with the program officer to ensure that their proposal will be human-focused enough to be competitive.
Proposals that cross institutional boundaries are encouraged.
Research groups working at national laboratories and within the federal government are allowable as partners, but funding to students doing research within these institutions must be channeled through an appropriate degree-granting institution.
For-profit companies may not participate in the application, but could be valuable partners in such training programs. Proposals that may offer students access to research opportunities involving work in or data from the for-profit sector are welcome.

Burroughs Wellcome Fund
Post Office Box 13901
Research Triangle Park, NC 27709-3901

Telephone: (919) 991-5100
Fax: (919) 991-5160

Biostatiscian, Epidemiologogist, Geneticist , Health Economist, Health Services Researcher, Molecular Biologist , Physician Researcher, Scientist, Toxicologist, Virologist
American Society for Microbiology/Coordinating Center for Infectious Diseases Program in Infectious Disease and Public Health Microbiology
American Society for Microbiology/Coordinating Center for Infectious Diseases
All Regions
01/15/2009
$46,000

ASM/CCID Program in Infectious Disease and Public Health Microbiology

Program
The program is sponsored by the American Society for Microbiology (ASM) and the Coordinating Center for Infectious Diseases (CCID), formerly known as the National Center for Infectious Diseases (NCID). The goal of ASM/CCID Fellowship is to support the development of new approaches, methodologies and knowledge in infectious disease prevention and control in areas within the public health mission of the CDC. The fellowship allows one to perform research in residence at the CCID which is headquartered at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. Eligible fields of study include:

Bacterial and Mycotic Diseases
Viral and Rickettsial Infections
Nosocomial Infections
HIV/AIDS
Vector-borne Infectious Diseases
Parasitic Diseases

Funding
The Fellowship provides an annual stipend (up to $42,188), health benefits (up to $3000 annually) for a maximum of 2 years, relocation benefits (up to $500), and (up to $2000 annually) for professional development for a maximum of 2 years.

Eligibility
The program is intended for individuals who either earned their doctorate degree or completed a primary residency within three years of their proposed start date. Applicants may not have a faculty position or be enrolled in a graduate degree program during the fellowship. Considerations will be given to individuals with more experience if there are compelling reasons. Qualified applicants will receive consideration without regard to race, creed, color, age, sex, or national origin.

Criteria for Selection
Applications are reviewed for (i) scientific merit and training potential of the research proposal, (ii) training resources and environment from the identified preceptor, and (iii) congruence with the Centers for Diseases public health mission.

Deadline
January 15th

Contact
ASM/CCID Postdoctoral Research Fellowship Program
Education Department
American Society for Microbiology
1752 N Street, N.W.
Washington, D.C. 20036
(202) 942-9295
E-mail: Fellowships-CareerInformation@asmusa.org

Microbiologist, Public Health Expert, Public Health Worker, Scientist, Virologist, Physician Researcher
International Society for Antiviral Research Awards
International Society for Antiviral Research
All Regions
10/15/2008
$7,500

International Society for Antiviral Research Awards

Gertrude Elion Memorial Lecture Award
GlaxoSmithKline has established sponsorship for the annual Gertrude Elion Memorial Lecture Award by committing annual funding of $10,000 to the International Society for Antiviral Research (ISAR). The award will be conferred at the time of the lecture at the annual conference of the Society. The funds will be used for minimal administrative fees, travel and per diem for the awardee, and the award will be in the amount of $7,500 (the award will be constant, expenses for travel and per diem will vary depending on where the awardee is coming from). The remainder will be kept in escrow for future Elion awards.

The Awards Committee of the ISAR will select the recipient. The award will be given to an outstanding scientist, not necessarily in the field of antiviral research but certainly someone who has made considerable contributions to the scientific field directly or peripheral to it. It should be a senior scientist (basic or clinical) of international stature. If the nominee had some ties to Dr. Elion, this would be considered in a favorable light. The main selection criterion will be scientific prominence. In addition to scientific preeminence, the recipient should have some of the characteristics typical of "Trudy" -- a genuine love of science, not only admired but also respected, a reputation for scientific integrity and approachability, especially to young scientists. The awardee will be asked to give a 45-minute lecture at the annual meeting.

The membership will be asked to submit nominations to the Award Committee by October 15 for the next award. In addition to the name, the nomination should include a paragraph substantiating the nomination. The Committee will consider these nominations and will submit nominations themselves. The list will then be narrowed down by the Committee to two to three finalists and the Committee will then select the awardee from that list. The name of the Awardee will be submitted to the Chair of the Program Committee in time for the placement in a prominent position in the Annual Program. The name will also be submitted to the President of the ISAR for his/her letter notifying the recipient of the Award and also notifying GlaxoSmithKline of the selection.

William Prusoff Young Investigator Lecture Award
Bristol-Myers Squibb (BMS) has endowed the William Prusoff Young Investigator Lecture Award, which will be awarded annually by the International Society for Antiviral Research (ISAR). The award will be conferred at the time of the lecture at the annual conference of the Society. The income from the endowment will be used for minimal administrative fees, travel, per diem, a plaque and a cash award for the awardee. The remaining funds will stay in the endowment account for future awards.

The ISAR and BMS are delighted to enter into this joint project to honor one of the most talented and beloved members of the Society, Bill Prusoff who has been a loyal member of the Society since its inception. His contributions to the development of antivirals, which have succeeded to clinical use, are legendary; his dedication to mentoring young scientists makes this award in his name truly appropriate.

The Awards Committee, supplemented by representation from BMS, will select the recipient. The award will be given to an outstanding young scientist (not older than 45 years of age) who has demonstrated dedication and excellence in the field of antiviral research (basic or clinical, synthetic or pharmacological) and future potential for contribution to the field and the society. The award is intended to encourage young investigators in the field and by definition should not be a fully developed scientist. The ISAR membership will be invited to submit nominations following the published criteria by October 15 for the next award. The Awards Committee will select the awardee and submit his/her name to the Chair of the Program Committee in time for the placement in the annual program; the awardee will make a presentation on his/her work. The name will also be submitted to the President of the ISAR for his/her letter notifying the recipient as well as BMS of the selection.

Eligibility Criteria

1. Nomination for the award must be made by a member of the International Society for Antiviral Research.

2. The nominee must be not older than 45 years of age on January 1 of the year in which the award will be made.

3. The nomination must include a letter of recommendation, by the person making the nomination, outlining accomplishments and the curriculum vitae of the candidate.

4. Peer recognition and productivity in the area of antiviral research evidenced by:

* number and quality of peer reviewed publications
* number and quality of presentations at national/international meetings
* amount of responsibility (academic and/or industry).

5. Nominee should have potential for contribution to antiviral research and the Society.

Other criteria, which may be considered, include service to the antiviral research community evidenced by:

* service to the ISAR or service to National or International Health or science organizations; ( e.g. serving on a Study Section of the National Institutes of Health)
* service to other professional organizations

The nominations will be received by the Chairman of the ISAR Awards Committee and reviewed by the Committee, who will make the selection. The President of the Society will notify the awardee. as well as, BMS, of the selection.

The awardee will be invited to make a presentation at the next International Conference on Antiviral Research, where the award will be presented.

Nominations for the Elion and Prusoff Awards should be sent to the Chair of the Awards Committee

Dr. George J. Galasso
636 Crocus Drive Rockville, MD 20850-2045
Fax 301 762-7864

e-mail galassog@att.net

Distinguished Investigator, Distinguished Scholar, Distinguished Scientist, Established Investigator, Scientist, Senior Investigator, Senior Researcher, Virologist, Young Investigator, Young Scientist
Skoll Awards for Social Entrepreneurship
Skoll Foundation
All Regions
11/04/2008
$0
Skoll Awards for Social Entrepreneurship Guidelines
"Many of the problems of our modern world, ranging from disease to drugs to crime to terrorism, derive from the inequalities between the rich and the poor . . . be they rich nation versus poor nation or rich community versus poor community. It is in the best interests of the well-off to help empower those who are not as well-off to improve their lives." —Jeff Skoll

What's New:
• Year-round application and award process
• 24-month wait period for declined applications
• Eligibility quiz

The Skoll Foundation’s mission is to advance systemic change to benefit communities around the world by investing in, connecting and celebrating social entrepreneurs. We believe that social entrepreneurs see opportunities where others see problems and crises. They apply innovative solutions to social and environmental issues, empowering people and communities to envision and create positive change. They work in many kinds of organizations, including nonprofits, social purpose ventures such as community development banks, and hybrid organizations that mix elements of nonprofit and for-profit organizations.

The Skoll Foundation believes that social entrepreneurs represent a powerful force for large-scale impact or equilibrium change. Their work has the potential to reduce economic disparities, increase opportunities for the disadvantaged, promote healthy communities, and increase the interpersonal and intercultural understanding that is the foundation for world peace.

The Skoll Awards for Social Entrepreneurship
The Skoll Awards for Social Entrepreneurship support social entrepreneurs whose work has the potential for large-scale influence on critical challenges of our time: environmental sustainability, health, tolerance and human rights, institutional responsibility, economic and social equity, and peace and security. These issues are at the heart of the foundation’s vision of empowering people to create a peaceful, prosperous, sustainable world. Within these issues, we are particularly interested in applications from social entrepreneurs working in five critical sub-issue areas that threaten the survival of humanity – climate change, nuclear proliferation, global pandemics, conflict in the Middle East and water scarcity.

Skoll social entrepreneurs are innovators who have tested and proved their approach, are poised to replicate or scale up their work to create equilibrium change and engage others with a message that resonates with individuals whose resources are crucial to advancing these solutions. The Skoll Awards are designed for leaders who contribute value to a peer network committed to continuous learning. By telling their stories, they join in the foundation’s ongoing celebration of the power of social entrepreneurs.

The Skoll Awards provide later-stage, or mezzanine, funding, which is generally structured as a $1 million award paid out over three years, subject to payment limitations described below under Budget Guidance. In most cases, the grant is provided for core support to help organizations expand their programs and capacity to deliver long-term, sustainable equilibrium change. The Skoll Awards are not intended for new or early-stage programs or initiatives. Programs submitted for consideration should have a track record of no less than three years. In addition to core support, the Skoll Foundation supports the participation of Award recipients in the annual Skoll World Forum on Social Entrepreneurship.

Deadline for Applying:
Applications are accepted and reviewed on a year-round basis, with successful applicants receiving initial funding installments shortly after decisions are made. Regular deadlines (listed below and updated regularly) assist us in managing the internal review process for these applications, a process that takes a minimum of six months to be completed. Awards will be presented publicly at a ceremony at the Skoll World Forum, which occurs at the end of every March in Oxford, England.

Please note the following application deadlines:

August 5, 2008.
November 4, 2008.

We will post future deadlines as they become available.

Please note that, starting in August 2007, applicants who are not selected must wait 24 months before reapplying.

How to Apply
Please note that the selection process for Skoll Awards for Social Entrepreneurship is highly competitive. Each year the Skoll Foundation receives hundreds of applications for the small number of Awards offered, which means that many fine organizations are not selected for an Award. We have enormous regard for the important work being done by all of our applicants, whether they are selected for an Award or not.

Our application process is designed to select organizations that most closely align with our criteria. We urge applicants to complete the Eligibility Quiz to assess whether their organization meets our selection criteria.

Changes in the Application Process:

In 2007 the Skoll Foundation revised its application process and materials. There are three major changes in how the program is administered:

Applications are accepted and reviewed on a year-round basis, with successful applicants receiving initial funding installments shortly after decisions are made. Regular deadlines (listed below and updated regularly) assist us in managing the internal review process for these applications, a process that takes a minimum of six months to be completed. Awards will be presented publicly at a ceremony at the Skoll World Forum on Social Entrepreneurship, which occurs at the end of every March in Oxford, England.

Starting in August 2007, applicants who are not selected must wait 24 months before reapplying. This restriction is not retroactive; therefore, applicants who applied prior to 2007 may reapply if they believe that they now fit the Skoll Award criteria.
All applicants must complete an Eligibility Quiz before filling out the Online Application. The Eligibility Quiz is designed to help applicants assess their competitiveness and avoid preparing an application that is not likely to match Skoll’s selection criteria.
Application Process

Below is a description of the application process.

The first stage is the Eligibility Quiz. This tool is intended to help applicants assess their eligibility and potential competitiveness for a Skoll Award. At the end of the quiz, applicants are given a code that allows them to access the application. Applicants cannot move forward to the next phase until they have completed the Eligibility Quiz. However, you can view a preview of the application before taking the quiz.
The second stage is the Online Application. After taking the Eligibility Quiz, applicants who feel that their organization is eligible can proceed to completing an Online Application that requests key organizational details and brief answers to 10 questions. Skoll staff will review all applications. Those that are less competitive or do not fit our criteria will be declined at this stage.
The third stage is an invitation to submit a Full Proposal. Applicants selected to move forward in the process will be contacted by a program officer and invited to submit a Full Proposal. We anticipate that between 25 to 35 applicants will be asked to submit Full Proposals each year.
The fourth stage is Due Diligence. This process usually includes interviews, a site visit, reference checks, follow-up questions, an in-depth financial review and a discussion of grant objectives. We expect that approximately half of the organizations that are invited to submit Full Proposals will move on to the Due Diligence stage.
The final stage is the Selection of the Awardees. Decisions will take place on a year-round basis following completion of Due Diligence. We anticipate making eight to 12 Awards during each 12-month cycle.
Timeline:

Applications are accepted year round, with black-out periods during holidays, system maintenance and around Skoll Foundation events.
Applications are acknowledged electronically, usually within minutes of submission.
The application decision and, for successful applicants, an invitation to submit a Full Proposal occurs within six months of submission of an application.
Due Diligence takes several weeks to several months, depending on the schedule and project complexity.
Award decisions and funding are made year round.
All awards will be publicly celebrated during a ceremony at the Skoll World Forum in March of each year, regardless of the grant approval date.
Allied Health Professional, Health Economist, Health Educator, Public Health Expert, Public Health Worker, Social Worker
Burroughs Wellcome Fund Grants in Infectious Diseases
Burroughs Wellcome Fund
All Regions
11/03/2008
$0

Infectious Disease

Application Deadline: November 3, 2008
Accepting electronic applications only.

The Burroughs Wellcome Fund has supported research in infectious disease since 1981, when it began funding modern molecular approaches to understanding what have been called the great neglected diseases – malaria, the pathogenic fungi, and human parasites – that primarily affect people in underdeveloped countries. Since that time, much more attention has been paid to the urgent needs of these fields. In 2000, the Fund decided to turn its attention to the larger issues of human-pathogen interactions in these infectious diseases and others, opening the door for funding work in bacterial and viral diseases. BWF’s Investigators in the Pathogenesis of Infectious Disease program is designed to incorporate elements of previously funded areas of research, and to focus primarily on the interaction of pathogens with their human hosts.

http://www.bwfund.org/programs/infectious_disease/index.html

Physician Researcher, Scientist, Virologist
Bristol-Myers Squibb
Bristol-Myers Squibb
All Regions
12/31/2008
$0
Bristol-Myers Squibb will consider support of an IST which meets the criteria as described under our Policy Statement. ISTs must be medically appropriate and scientifically valid. While BMS will consider requests for clinical research trials in all clinical and therapeutic areas, we currently give priority to proposals in the following therapeutic areas: Cardiovascular/Metabolics, Infectious Diseases, Neuroscience, Oncology, Immunology, and Virology. Bristol-Myers Squibb maintains a strict policy of not exercising any influence or control over the design of any investigator initiated clinical research trial supported by BMS.